IQVIA Analytics Link Ecosystem establishes deep connections across our key data assets.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESParkinson's disease is a progressive neurodegenerative disorder primarily caused by the loss of dopamine producing neurons in the substantia nigra, a midbrain structure in the brain crucial for motor control, reward, and cognitive functions, leading to manifestation of motor symptoms called parkinsonism like tremors, bradykinesia, rigidity as well as postural instability. It was first described by James Parkinson in 1817.
By the time symptoms appear, 60% or more of these neurons are lost. The disease can also affect norepinephrine production potentially causing non-motor symptoms like fatigue and blood pressure changes. The histological hallmark of Parkinson's disease is the presence of the aggregation of alpha-synuclein into Lewy bodies within neurons.
Parkinson's disease affects 1 to 2 per 1000 individuals, with prevalence increasing to 1% of the population over 60 years. The condition is more common in men, and genetic predisposition is a factor in 5% to 10% of cases. Globally, over 10 million people are estimated to live with Parkinson's disease.
Parkinson's disease is diagnosed clinically, based on patient history, symptoms, and physical examination and an accurate diagnosis in initial stages may be difficult. While no definitive lab or imaging test exists, MRI, Dopamine Transporter Scan, and blood work may support the diagnosis or exclude conditions mimicking Parkinson's disease.
This article provides an update on current treatment options for Parkinson's disease and outlines the latest development activities including ongoing clinical trials of key experimental drugs with data sourced from IQVIA Pipeline Link and IQVIA Trial Link.
Download the article for key insights into Parkinson's treatment, trials, and pipeline innovation. Essential reading for pharma leaders seeking strategic advantage in this fast-evolving market.
IQVIA Analytics Link Ecosystem establishes deep connections across our key data assets.